On July 2nd, Nature Medicine published research co-authored by three AFAR Grantees, Madison Doolittle, PhD, and Nathan LeBrasseur, PhD, MS, as well as James L. Kirkland, MD, PhD, who is also AFAR’s Immediate Past President. The research explores how drugs that selectively kill senescent cells may benefit otherwise healthy older women but are not a "one-size-fits-all" remedy. Specifically, these drugs may only benefit people with a high number of senescent cells, a Mayo Clinic press release explains.
Dr. Doolittle is a 2021 Glenn Foundation for Medical Research Postdoctoral Fellowships in Aging Research recipient.
Dr. LeBrasseur is a 2002 Glenn/AFAR Scholarship for Research in the Biology of Aging recipient, and a 2019 Vincent Cristofalo Rising Star Award in Aging Research recipient.
Dr. Kirkland is an AFAR board Member, recent a 2020 Irving S. Wright Award of Distinction recipient and a 2012 Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award recipient.
Read “Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial” here.
Learn more in related Mayo Clinic press release here.
